MAGOHB: A Potential Drug Target and Biomarker (G55110)

Target Name: MAGOHB

NCBI ID: G55110

MAGOHB

MAGOHB: A Potential Drug Target and Biomarker

MAGOHB (MAGohC1-OH-N-acetyl-L-histidine) is a novel protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. MAGOHB is a member of the histidine acetyltransferase family (HATs) and is expressed in a variety of tissues and cells, including tissues of the brain, heart, liver, and muscle.

MAGOHB's Unique Characteristics

MAGOHB has several unique characteristics that make it an interesting drug target and biomarker. First, it is a type of HAT that is expressed in the brain and is involved in the regulation of central nervous system (CNS) function. Second, MAGOHB is a potent inhibitor of the neurotransmitter acetylcholine, which is involved in the development and maintenance of neural circuits. Third, MAGOHB is involved in the regulation of cellular processes that are critical for cell survival, such as cell proliferation, migration, and apoptosis.

Drug Target Potential

MAGOHB's potential as a drug target is due to its involvement in the regulation of CNS function and its ability to inhibit neurotransmitter acetylcholine. The neurotransmitter acetylcholine is involved in the development and maintenance of neural circuits, and MAGOHB's inhibition of its action could lead to the disruption of these circuits, which could lead to the pathophysiology of various psychiatric and neurological disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

MAGOHB's ability to inhibit neurotransmitter acetylcholine also makes it a potential target for treating neurotransmitter-related disorders, such as anxiety, depression, and PTSD. By blocking the action of neurotransmitters, MAGOHB could be a more effective treatment for these disorders than existing treatments.

Biomarker Potential

MAGOHB's potential as a biomarker is due to its unique expression patterns in various tissues and its involvement in the regulation of cellular processes that are critical for cell survival. MAGOHB is expressed in the brain and other tissues, and its levels have been shown to be elevated in a variety of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

MAGOHB's expression has also been shown to be associated with the development and progression of various cancers, including breast, ovarian, and prostate cancers. This suggests that MAGOHB may be a useful biomarker for cancer diagnosis and treatment.

Conclusion

MAGOHB is a novel protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique characteristics, including its expression in the brain and its ability to inhibit neurotransmitter acetylcholine, make it an interesting target for drug development. Additionally, MAGOHB's expression patterns in various tissues and its association with the development and progression of cancer make it a potential biomarker for disease diagnosis and treatment. Further research is needed to fully understand the potential of MAGOHB as a drug target and biomarker.

Protein Name: Mago Homolog B, Exon Junction Complex Subunit

Functions: Required for pre-mRNA splicing as component of the spliceosome (PubMed:28502770, PubMed:29301961, PubMed:30705154). Plays a redundant role with MAGOH in the exon junction complex and in the nonsense-mediated decay (NMD) pathway (PubMed:23917022)

The "MAGOHB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAGOHB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets